期刊文献+

子宫内膜癌患者血清及组织中YKL-40、IGF和SA表达及其临床意义 被引量:3

Clinical Significance and Expression of YKL-40,IGF and SA in Serum and Tissue of Endometrial Carcinoma
下载PDF
导出
摘要 目的探讨子宫内膜癌血清及子宫内膜组织中YKL-40、IGF及SA水平与其发生发展的关系。方法 76例子宫内膜癌患者作为观察组,另以76例健康同龄妇女作为对照组,然后采用ELISA法,检测两组患者血清YKL-40、IGF及SA水平并比较,另采用免疫组化检测两组子宫内膜组组织中上述指标的表达情况。结果观察组血清YKL-40、IGF-1、IGF-1R、IGF-2及SA水平均高于对照组,子宫内膜组织中其阳性率也高于对照组,且不同FIGO分期子宫内膜癌患者间也存在明显差异,经Logistic分析处理显示,上述指标均与子宫内膜癌的发生有密切关系。结论子宫内膜癌患者血清及子宫内膜组织中YKL-40、IGF及SA呈现异常的状态,且不同FIGO分期患者间差异也较为明显。 Objective To study the relationship between the expression of YKL-40,IGF and SA in serum and tissue of endometrial carcinoma and its development .Methods 76 patients with endometrial carcinoma were selected as the observation group,and 76 healthy women at the same age were selected as the control group ,and the serum YKL-40,IGF and SA levels of the 2 groups were compared ,immunohistochemical method was used to compare YKL-40,IGF and SA levels in endometrial tissues , and the relationship between those indexes and disease were analyzed by the Logistic analysis .Results The serum YKL-40,IGF-1,IGF-1R,IGF-2 and SA levels of the observation group were all higher than those of the control group ,positive rates in endome-trial tissues were all higher than those of the control group ,and the detection results in the observation group at different FIGO sta-ges of endometrial carcinoma had significant differences .Those indexes all had close relationship with the development of endome-trial carcinoma by Logistic analysis ,all P<0.05.Conclusion YKL-40,IGF and SA in the serum and tissue of patients with en-dometrial carcinoma have abnormal level ,and patients at different FIGO stages have significant difference .
作者 蒲芬
出处 《实用癌症杂志》 2014年第10期1210-1212,共3页 The Practical Journal of Cancer
关键词 血清 组织 YKL-40 IGF SA 子宫内膜癌 Serum Tissue YKL-40 IGF SA Endometrial carcinoma
  • 相关文献

参考文献8

二级参考文献96

  • 1刘喆,温宏武,王建六,魏丽惠.血清CA_(125)检测在子宫内膜癌中的价值[J].中国妇产科临床杂志,2003,4(4):257-260. 被引量:8
  • 2卢兆莲,罗南萍,胡志德,刘恒国,王瑞山.恶性肿瘤患者血清C肽水平的变化及意义[J].放射免疫学杂志,2006,19(6):494-494. 被引量:1
  • 3Jemal A,Murray T,Ward E,et al.Cancer statistics,2005.CA Cancer[J].Clin,2005,55(1):10-30.
  • 4Jeon YT,Park IA,Kim YB,et al.Steroid receptor expressions in endometrial cancer:clincal dignificance and epidemiological implication[J].Cancer Lett,2006,239(2):198-204.
  • 5Dupont J,Tanwar MK,Thaler HT,et al.Early detection and prognosis of ovarian cancer using serum YKL-40[J].J Clin Oncol,2004,22(16):3330-3339.
  • 6Johansen JS,Jensen BV,Roslind A,et al.Is YKL-40 a new therapeutic target in cancer[J].Expert Opin Ther Targets,2007,11:219-234.
  • 7Diefenbach CS,Shah Z,Iasonos A,et al.Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer[J].Gynecol Oncol,2007,104(2):435-442.
  • 8Ginath S,Menczer J,Fintsi Y,et al.Glezerman and I.Avinoach,Tissue and serum CA125 expression in endometrial cancer[J].Int J Gynecol Cancer,2002,12 (4):372-375.
  • 9Powell JL,Hill KA,Shiro BC,et al.Preoperative serum CA-125 levels in treating endometrial cancer[J].J Reprod Med,2005,50 (8):585–590.
  • 10Difenbach CS,Shah Z,Iasonos A,et al.Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer[J].Gynecol Oncol,2007,104:435-442.

共引文献43

同被引文献49

  • 1Saarelainen SK, Staff S, Peltonen N, et al. Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma[J].Tumour Biol,2014, 35(5):4651-4657.
  • 2Rinck-Junior JA, Oliveira C, LourenCo GJ, et al.Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer[J].J Can- cer Res Clin Oncol,2015,141 (1):69-73.
  • 3Richard G. Moore,Amy K. Brown,M. Craig Miller,Donna Badgwell,Zhen Lu,W. Jeffrey Allard,C.O. Granai,Robert C. Bast,Karen Lu.Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus[J]. Gynecologic Oncology . 2008 (2)
  • 4Laura J. Havrilesky,Clark M. Whitehead,Jennifer M. Rubatt,Robert L. Cheek,John Groelke,Qin He,Douglas P. Malinowski,Timothy J. Fischer,Andrew Berchuck.Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence[J]. Gynecologic Oncology . 2008 (3)
  • 5Richard G. Moore,Amy K. Brown,M. Craig Miller,Steven Skates,W. Jeffrey Allard,Thorsten Verch,Margaret Steinhoff,Geralyn Messerlian,Paul DiSilvestro,C.O. Granai,Robert C. Bast.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecologic Oncology . 2007 (2)
  • 6Laura Zanotti,Eliana Bignotti,Stefano Calza,Elisabetta Bandiera,Giuseppina Ruggeri,Claudio Galli,Germana Tognon,Monica Ragnoli,Chiara Romani,Renata A. Tassi,Luigi Caimi,Franco E. Odicino,Enrico Sartori,Sergio Pecorelli,Antonella Ravaggi.Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome[J]. Clinical Chemistry and Laboratory Medicine . 2012 (12)
  • 7Gillan Lindsay,Matei Daniela,Fishman David A,Gerbin C S,Karlan Beth Y,Chang David D.Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Research . 2002
  • 8Hidefumi Sasaki,Chih-Yi Yu,Meiru Dai,Carmen Tam,Massimo Loda,Daniel Auclair,Lan Bo Chen,Anthony Elias.??Elevated Serum Periostin Levels in Patients with Bone Metastases from Breast but not Lung Cancer(J)Breast Cancer Research and Treatment . 2003 (3)
  • 9Yongjung Park,Jong-Han Lee,Duck Jin Hong,Eun Young Lee,Hyon-Suk Kim.??Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases(J)Clinical Biochemistry . 2011 (10)
  • 10Li J,Chen H,Mariani A,et al.HE4 (WFDC2)promotes tumor growth in endometrial cancer cell lines. Int J Mol Sci . 2013

引证文献3

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部